

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (previously presented) Ondansetron hydrochloride dihydrate having a purity of at least about 99.0% by weight and an exo-methylene by-product content of less than 0.01% by weight.

2. (previously presented) Ondansetron hydrochloride dihydrate having a purity of at least about 99.5% by weight and an exo-methylene by-product content of less than 0.01% by weight.

3. (previously presented) Ondansetron hydrochloride dihydrate having a purity of at least about 99.9% by weight and an exo-methylene by-product content of less than 0.01% by weight.

4-51. (canceled)

52. (previously presented) A pharmaceutical formulation comprising a therapeutically effective amount of ondansetron hydrochloride dihydrate and at least one pharmaceutically acceptable excipient, wherein the ondansetron hydrochloride dihydrate has a purity of at least about 99.0% by weight and an exo-methylene by-product content of less than 0.01% by weight.

53. (previously presented) The pharmaceutical formulation of claim 52, wherein the ondansetron hydrochloride dihydrate has a purity of at least about 99.5% by weight and an exo-methylene by-product content of less than 0.01% by weight.

54. (previously presented) The pharmaceutical formulation of claim 52, wherein the ondansetron hydrochloride dihydrate has a purity of at least about 99.9% by weight and an exo-methylene by-product content of less than 0.01% by weight.